<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40930600</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1876-7605</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>17</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>JACC. Cardiovascular interventions</Title><ISOAbbreviation>JACC Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold: The NeoVas Randomized Trial.</ArticleTitle><Pagination><StartPage>2107</StartPage><EndPage>2115</EndPage><MedlinePgn>2107-2115</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcin.2025.06.036</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1936-8798(25)01775-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous trials have demonstrated increased 5-year risks for adverse clinical events after coronary artery implantation of poly-l-lactic acid-based bioresorbable scaffolds (BRS) compared with cobalt chromium (CoCr) everolimus-eluting stents (EES).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study was to evaluate the 5-year clinical outcomes of the novel sirolimus-eluting NeoVas BRS compared with CoCr EES.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 560 patients with single de novo native coronary artery lesions with reference vessel diameter 2.5 to 3.75 mm and lesion length &#x2264;20 mm were randomized 1:1 to NeoVas BRS vs CoCr EES and followed for 5 years. Optical coherence tomography and fractional flow reserve were performed in a prespecified subgroup of 166 patients at 3-year follow-up.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 5-year target lesion failure rates were 9.5% in the NeoVas group and 7.2% in the CoCr EES group (HR: 1.33; 95% CI: 0.74 to 2.38; P = 0.33). The 5-year rates of device thrombosis were not different between the groups (1.5% vs 0.7%, respectively; HR: 2.05; 95% CI: 0.37 to 11.16; P = 0.45). In a subset of patients in whom optical coherence tomography was performed at 3 years, it demonstrated that NeoVas was substantially absorbed (72.3% &#xb1; 13.2%). Fractional flow reserve was not significantly different between the 2 groups either postprocedure or at 3 years (0.89 &#xb1; 0.07 vs 0.90 &#xb1; 0.05, respectively; P = 0.11).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">At 5-year follow-up, target lesion failure and stent thrombosis rates were comparable after NeoVas BRS and CoCr EES implantation in noncomplex lesions. However, comparability or the potential signs of harm of NeoVas BRS should be investigated in appropriately sized randomized trials in the future. (NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial; NCT02305485).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Guosheng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Sir Run Run Shaw Hospital, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaozeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Xijing Hospital, the Fourth Military Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Nanfang Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Wuhan Asia Heart Hospital, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Quan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lianglong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Fujian Medical University Union Hospital, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Huiliang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, General Hospital of Chinese People's Armed Police Forces, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Aero Space Center Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Zuyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, the First Affiliated Hospital of Xi'an Jiongtong University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Chuanyu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Henan Provincial People's Hospital, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shenghua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiology, the Second Xiangya Hospital of Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Changdong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yaling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China. Electronic address: hanyalingnh@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Gregg W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NeoVas Randomized Controlled Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02305485</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Cardiovasc Interv</MedlineTA><NlmUniqueID>101467004</NlmUniqueID><ISSNLinking>1936-8798</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002317">Cardiovascular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002858">Chromium Alloys</NameOfSubstance></Chemical><Chemical><RegistryNumber>9HW64Q8G6G</RegistryNumber><NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011091">Polyesters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020099">Coated Materials, Biocompatible</NameOfSubstance></Chemical><Chemical><RegistryNumber>459TN2L5F5</RegistryNumber><NameOfSubstance UI="C033616">poly(lactide)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020341" MajorTopicYN="Y">Absorbable Implants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011474" MajorTopicYN="N">Prosthesis Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002317" MajorTopicYN="Y">Cardiovascular Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="Y">Sirolimus</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054855" MajorTopicYN="Y">Drug-Eluting Stents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002858" MajorTopicYN="N">Chromium Alloys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053805" MajorTopicYN="N">Fractional Flow Reserve, Myocardial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068338" MajorTopicYN="Y">Everolimus</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003328" MajorTopicYN="N">Coronary Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003331" MajorTopicYN="Y">Coronary Vessels</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017023" MajorTopicYN="N">Coronary Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011091" MajorTopicYN="N">Polyesters</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020099" MajorTopicYN="Y">Coated Materials, Biocompatible</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioresorbable scaffold</Keyword><Keyword MajorTopicYN="N">coronary artery disease</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">sirolimus-eluting stent(s)</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures The NeoVas randomized controlled trial was sponsored by Lepu Medical. Dr Stone has received speaker honoraria from Medtronic, Pulnovo Medical, Abiomed, Amgen, Boehringer Ingelheim; has served as a consultant to Abbott, Daiichi-Sankyo, Ablative Solutions, CorFlow, Cardiomech, Robocath, Miracor, Vectorious, Apollo Therapeutics, Elucid Bio, Cardiac Success, Valfix, TherOx, HeartFlow, Neovasc, Ancora, Occlutech, Impulse Dynamics, Adona Medical, Millennia Biopharma, Oxitope, HighLife, Elixir, Remote Cardiac Enablement, and Aria; and has equity and options with Cardiac Success, Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWAVE, Orchestra Biomed, Aria, Valfix, Xenter. Dr. Stone&#x2019;s employer, Mount Sinai Hospital, receives research grants from Shockwave Medical, Abbott, Abiomed, Bioventrix, Cardiovascular Systems, Phillips, Biosense Webster, Vascular Dynamics, Pulnovo Medical, and V-Wave. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>10</Day><Hour>20</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40930600</ArticleId><ArticleId IdType="doi">10.1016/j.jcin.2025.06.036</ArticleId><ArticleId IdType="pii">S1936-8798(25)01775-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>